Dr. Michael Brines
Rockefeller University
Biography & Research Background
Michael Brines, MD, PhD, is an endocrinologist and co-founder of Araim Pharmaceuticals, Inc. (Tarrytown, NY). A graduate of Rockefeller University, Dr. Brines identified that the tissue-protective properties of erythropoietin (EPO) were mediated by a specific receptor (the Innate Repair Receptor) distinct from the erythropoietic receptor. He played a lead role in engineering ARA-290 based on the three-dimensional structure of EPO’s helix B to selectively activate the IRR without stimulating red blood cell production. He also served at The Feinstein Institutes for Medical Research (Manhasset, NY) and has authored over 40 publications on EPO-derived tissue protection. Michael Brines is being referenced as one of the leading scientists involved in the research and development of ARA-290. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Michael Brines is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Michael Brines is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.